Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.

Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-

Melanoma*/pathology ; Liver Neoplasms* ; Uveal Neoplasms*/pathology; Humans ; Male ; Middle Aged ; Female ; Positron Emission Tomography Computed Tomography ; Prognosis ; Fluorodeoxyglucose F18 ; Retrospective Studies ; Uveal Melanoma

Background: Uveal melanoma metastasizes to the liver. We aimed to explore the metabolic activity of liver metastases (LM) as a biomarker for survival.
Methods: We analyzed newly diagnosed patients with metastatic UM (MUM) with LM detected by liver-directed imaging and had undergone a PET/CT at diagnosis.
Findings: 51 patients were identified between 2004 and 2019. Median age was 62 years, 41% male and 22% ECOG ≥1. LDH, ALP, and GGT were elevated in 49%, 37%, and 57% of patients. Median LM SUVmax was 8.5 (3-42.2). Same size lesions presented a wide range of metabolic activity. Median OS was 17.3 m (95% CI:10.6-23.9). Patients with SUVmax ≥8.5 had an OS of 9.4 m (95% CI:6.4-12.3), whereas patients with SUVmax <8.5 had an OS of 38.4 m (95% CI:21.4-55.5; p < 0.0001, HR = 2.9). We observed similar results when studying M1a disease separately. Multivariate analysis showed SUVmax as an independent prognostic factor for the whole population and those with M1a disease.
Interpretation: Increased metabolic activity of LM seems to be an independent predictor of survival. MUM is a heterogeneous disease and metabolic activity probably reflects a different intrinsic behavior.
(© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4187-4195. (PMID: 31596927)
JAMA Ophthalmol. 2015 Apr;133(4):376-83. (PMID: 25555246)
Eur J Surg Oncol. 2010 Feb;36(2):189-94. (PMID: 19775851)
Cancer Cell. 2017 Aug 14;32(2):204-220.e15. (PMID: 28810145)
Melanoma Res. 2011 Jun;21(3):217-22. (PMID: 21467954)
Cancer Med. 2023 Jul;12(13):14062-14071. (PMID: 37211960)
J Clin Oncol. 2021 Feb 20;39(6):586-598. (PMID: 33417511)
Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):91-95. (PMID: 30122854)
Cancers (Basel). 2019 Jun 13;11(6):. (PMID: 31200439)
Eur J Ophthalmol. 2012 Mar-Apr;22(2):236-43. (PMID: 21959680)
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1682-91. (PMID: 23824464)
Br J Ophthalmol. 2014 Dec;98(12):1659-65. (PMID: 25084771)
J Clin Oncol. 2005 Nov 1;23(31):8076-80. (PMID: 16258106)
Cancer Imaging. 2015 Nov 20;15:19. (PMID: 26589835)
Crit Rev Oncol Hematol. 2020 Sep;153:103044. (PMID: 32673997)
Cancer Res. 2004 Oct 15;64(20):7205-9. (PMID: 15492234)
J Clin Oncol. 2021 Feb 20;39(6):599-607. (PMID: 33125309)
Jpn J Ophthalmol. 2019 Mar;63(2):197-209. (PMID: 30796549)
Melanoma Res. 2012 Feb;22(1):63-9. (PMID: 22027909)
Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1774-82. (PMID: 19495748)
Cancer Res Treat. 2018 Oct;50(4):1130-1139. (PMID: 29198096)
Clin Ophthalmol. 2016 Oct 25;10:2113-2119. (PMID: 27822007)
Am J Ophthalmol. 2004 Dec;138(6):936-51. (PMID: 15629284)
Melanoma Res. 2012 Jun;22(3):271-7. (PMID: 22516965)
Ocul Oncol Pathol. 2018 Apr;4(3):145-151. (PMID: 29765944)
N Engl J Med. 2021 Sep 23;385(13):1196-1206. (PMID: 34551229)
Ann Oncol. 2019 Aug 1;30(8):1370-1380. (PMID: 31150059)

Keywords: PET/CT; glucose metabolism; liver metastasis; prognostic; uveal melanoma

0Z5B2CJX4D (Fluorodeoxyglucose F18)

Date Created: 20230522 Date Completed: 20230721 Latest Revision: 20250103

20250114

PMC10358185

10.1002/cam4.6058

37211960